Toggle Summary December 18, 2015
Minerva Achieves Enrollment Target in Phase IIb Trial With MIN-101
WALTHAM, Mass., Dec. 18, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it has met its enrollment target of 234 patients in
View HTML
Toggle Summary December 9, 2015
Minerva Provides Year-End Update on Clinical Trials With Three Central Nervous System Product Candidates
Patient Enrollment Progress During 2015 Confirms Timeline Expectations for Topline Data Availability From Four Trials in First Half of 2016
View HTML
Toggle Summary November 13, 2015
Minerva Neurosciences to Present at Jefferies 2015 London Healthcare Conference on November 18, 2015
View HTML
Toggle Summary November 5, 2015
Minerva Neurosciences Reports Third Quarter 2015 Financial Results and Business Updates
View HTML
Toggle Summary November 2, 2015
Minerva Neurosciences Announces Appointment of Dr. David Kupfer to Its Board of Directors
View HTML
Toggle Summary October 29, 2015
Minerva Neurosciences to Report Third Quarter 2015 Financial Results and Host Conference Call on November 5, 2015
View HTML
Toggle Summary September 24, 2015
Minerva Neurosciences Provides Update on Clinical Development Program With MIN-202, Selective Orexin-2 Receptor Antagonist
Patient Recruitment Ongoing in Trials in Insomnia Disorder and Adjunctive Major Depressive Disorder
View HTML
Toggle Summary September 2, 2015
Minerva Neurosciences to Present at Baird 2015 Healthcare Conference on September 9, 2015
View HTML
Toggle Summary August 5, 2015
Minerva Neurosciences Reports Second Quarter 2015 Financial Results and Business Updates
View HTML
Toggle Summary July 29, 2015
Minerva Neurosciences to Report Second Quarter 2015 Financial Results and Host Conference Call on August 5, 2015
View HTML